AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
AnaptysBio Price Performance
NASDAQ ANAB traded down $0.69 during trading on Tuesday, reaching $34.88. 233,203 shares of the company’s stock were exchanged, compared to its average volume of 328,526. The business has a 50 day moving average price of $35.79 and a 200-day moving average price of $27.95. The stock has a market capitalization of $952.89 million, a P/E ratio of -5.68 and a beta of -0.29. AnaptysBio, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $41.31.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts forecast that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.
Hedge Funds Weigh In On AnaptysBio
Analyst Upgrades and Downgrades
ANAB has been the topic of several recent analyst reports. Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.30.
Check Out Our Latest Stock Report on AnaptysBio
About AnaptysBio
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Read More
- Five stocks we like better than AnaptysBio
- How to Use the MarketBeat Dividend Calculator
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Learn Technical Analysis Skills to Master the Stock Market
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Choose Top Rated Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.